Understand which treatments for multiple myeloma are winning the hearts and minds of medical oncologists and haematologists in the US
There are various treatment options available to US medical oncologists and haematologists to treat multiple myeloma. Clearly some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?
This report gives a unique insight into the overall brand health of 9 leading treatments for multiple myeloma currently being used in the US from companies including Celgene, AbbVie, Amgen, BMS, Novartis and Takeda.
100 US medical oncologists and haematologists were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out.
Interested in the European market? Click here to see the EU5 Edition.
NPS+ Multiple Myeloma (US) offers valuable insight into brand loyalty from the perspective of those currently prescribing treatments for multiple myeloma to patients. You’ll discover:
We surveyed 100 US-based medical oncologists and haematologists chosen from the largest community of validated physicians in the world.
We conducted the survey between October 4-12, 2018.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved